Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) Research & Development (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Research & Development data on record, last reported at $45.5 million in Q3 2025.

  • For Q3 2025, Research & Development rose 30.5% year-over-year to $45.5 million; the TTM value through Sep 2025 reached $161.3 million, up 21.86%, while the annual FY2024 figure was $138.5 million, 2.35% up from the prior year.
  • Research & Development reached $45.5 million in Q3 2025 per GOSS's latest filing, up from $41.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $45.5 million in Q3 2025 and bottomed at $30.0 million in Q4 2023.
  • Average Research & Development over 4 years is $38.0 million, with a median of $37.8 million recorded in 2023.
  • Peak YoY movement for Research & Development: dropped 29.9% in 2023, then surged 30.5% in 2025.
  • A 4-year view of Research & Development shows it stood at $41.5 million in 2022, then fell by 27.8% to $30.0 million in 2023, then grew by 20.49% to $36.1 million in 2024, then increased by 26.11% to $45.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $45.5 million in Q3 2025, $41.6 million in Q2 2025, and $38.0 million in Q1 2025.